<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/immunomedics-inc-nasdaqimmu-short-interest-down-5-5-in-october.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T14:52:32+00:00"/>
    <meta property="og:title" content="Immunomedics, Inc. (NASDAQ:IMMU) Short Interest Down 5.5% in October"/>
    <meta property="og:description" content="Immunomedics, Inc. (NASDAQ:IMMU) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 29,940,000 shares, a drop of 5.5% from the September 30th total of 31,680,000 shares. Based on an average daily trading volume, of 2,220,000 shares, the short-interest ratio is currently 13.5 days. […]"/>
  </head>
  <body>
    <article>
      <h1>Immunomedics, Inc. (NASDAQ:IMMU) Short Interest Down 5.5% in October</h1>
      <address><time datetime="2019-11-18T14:52:32+00:00">18 Nov 2019, 14:52</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/immunomedics-incorporated-logo.jpg"/>
      </figure>
      <p>Immunomedics, Inc. (NASDAQ:IMMU) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 29,940,000 shares, a drop of 5.5% from the September 30th total of 31,680,000 shares. Based on an average daily trading volume, of 2,220,000 shares, the short-interest ratio is currently 13.5 days. Approximately 16.5% of the company’s stock are short sold.</p>
      <p>In other Immunomedics news, Director Avoro Capital Advisors Llc purchased 1,000,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average price of $13.23 per share, for a total transaction of $13,230,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at <a href="https://www.sec.gov/Archives/edgar/data/722830/000090266419003903/xslF345X03/ownership.xml">this link</a>. Also, insider Bryan Ball purchased 5,000 shares of the business’s stock in a transaction dated Thursday, October 3rd. The shares were acquired at an average price of $14.18 per share, for a total transaction of $70,900.00. Following the acquisition, the insider now directly owns 10,000 shares in the company, valued at approximately $141,800. The disclosure for this purchase can be found <a href="https://www.sec.gov/Archives/edgar/data/722830/000110465919053001/xslF345X03/a4.xml">here</a>. Company insiders own 9.40% of the company’s stock.</p>
      <p>Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase &amp; Co. raised its holdings in Immunomedics by 4.5% in the 2nd quarter. JPMorgan Chase &amp; Co. now owns 490,343 shares of the biopharmaceutical company’s stock worth $6,790,000 after acquiring an additional 21,135 shares during the period. BB&amp;T Securities LLC raised its holdings in Immunomedics by 78.4% in the 2nd quarter. BB&amp;T Securities LLC now owns 22,750 shares of the biopharmaceutical company’s stock worth $315,000 after acquiring an additional 10,000 shares during the period. C WorldWide Group Holding A S bought a new position in Immunomedics in the 2nd quarter worth $6,103,000. Fosun International Ltd raised its holdings in Immunomedics by 6.4% in the 2nd quarter. Fosun International Ltd now owns 250,433 shares of the biopharmaceutical company’s stock worth $3,468,000 after acquiring an additional 15,000 shares during the period. Finally, First Republic Investment Management Inc. bought a new position in Immunomedics in the 2nd quarter worth $151,000. Hedge funds and other institutional investors own 88.49% of the company’s stock.</p>
      <p>A number of research firms have recently weighed in on IMMU. Wells Fargo &amp; Co raised their price target on shares of Immunomedics from $14.00 to $16.00 and gave the company a “market perform” rating in a report on Monday, September 30th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=IMMU">ValuEngine</a> upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. B. Riley set a $28.00 price target on shares of Immunomedics and gave the company a “buy” rating in a report on Monday, September 30th. Jefferies Financial Group set a $22.00 price target on shares of Immunomedics and gave the company a “buy” rating in a report on Tuesday, September 10th. Finally, BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $26.22.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/IMMU/options/">IMMU</a> traded up $0.15 during trading on Monday, hitting $17.69. The stock had a trading volume of 50,683 shares, compared to its average volume of 1,598,386. The firm has a market cap of $3.35 billion, a PE ratio of -17.00 and a beta of 2.13. Immunomedics has a 12 month low of $11.55 and a 12 month high of $21.23. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.30. The company has a 50 day simple moving average of $15.59 and a 200-day simple moving average of $14.70.</p>
      <p>Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.09). During the same period in the previous year, the company posted ($0.34) EPS. As a group, sell-side analysts anticipate that Immunomedics will post -1.78 earnings per share for the current fiscal year.</p>
      <p>
        <b>Immunomedics Company Profile</b>
      </p>
      <p>Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/what-is-a-fibonacci-channel/">What is a Fibonacci Channel?</a></p>
    </article>
  </body>
</html>